Literature DB >> 62426

The natural modulation of the amplification phase of complement activation.

D T Fearon, M R Daha, J M Weiler, K F Austen.   

Abstract

As C3 cleavage represents the most critical step in the elaboration of the biologic effects of the complement system, the modulation of this reaction by formation and function of the C3b-dependent C3 convertase may well determine whether the initial activation of the complement sequence eventuates in beneficial or detrimental effects to the host. Stabilization of the amplification C3b-dependent convertase, C3bBb, is achieved with P and C3NeF, respectively, after their binding which exhibits different molecular and temperature requirements. Control of this amplifying step occurs at three levels: intrinsic decay of the inherently labile C3bBb convertase; extrinsic decay by displacement of Bb from the convertase with beta1H; and inactivation by C3bINA of C3b after its generation from native C3 or removal of protective Bb by intrinsic or extrinsic decay. In the presence of the stabilizing factors the control proteins must function in sequence with beta1H-mediated decay preceding C3b inactivation.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 62426     DOI: 10.1111/j.1600-065x.1976.tb00226.x

Source DB:  PubMed          Journal:  Transplant Rev        ISSN: 0082-5948


  5 in total

1.  Complement activation in asymptomatic patients with sickle cell anaemia.

Authors:  W A Wilson; E J Thomas; J G Sissons
Journal:  Clin Exp Immunol       Date:  1979-04       Impact factor: 4.330

2.  Immunological, structural and functional relationships between an anti-complementary protein from Crotalus atrox venom, cobra venom factor and human C3.

Authors:  J O Minta; D Man
Journal:  Immunology       Date:  1980-04       Impact factor: 7.397

3.  Meningococcal infection and proteolytic control.

Authors:  J M Stark; N Matthews; H C Ryley; B M Greenwood; L S Lewis; H C Whittle
Journal:  J Clin Pathol       Date:  1978-12       Impact factor: 3.411

4.  Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) Among Patients With Antiphospholipid Antibodies (aPL).

Authors:  Stephanie L Savelli; Robert A S Roubey; Kathryn J Kitzmiller; Danlei Zhou; Haikady N Nagaraja; Evan Mulvihill; Fatima Barbar-Smiley; Stacy P Ardoin; Yee Ling Wu; Chack-Yung Yu
Journal:  Front Immunol       Date:  2019-05-07       Impact factor: 7.561

5.  An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy.

Authors:  Yi Yang; Harriet Denton; Owen R Davies; Kate Smith-Jackson; Heather Kerr; Andrew P Herbert; Paul N Barlow; Matthew C Pickering; Kevin J Marchbank
Journal:  J Am Soc Nephrol       Date:  2018-03-27       Impact factor: 10.121

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.